复发头颈鳞状细胞癌患者接受IMRT或质子治疗的根治性高剂量再程放疗:结局及失败模式分析
研究分析了23例接受根治性再程放疗的复发头颈鳞状细胞癌患者,其中52.2%接受IMRT、47.8%接受质子治疗,CTV中位最大剂量66 Gy。中位随访41.3个月后18例出现局部区域复发,其中8例(44.4%)位于既往再程放疗野内。质子治疗组无病生存期显著更长(p=0.031),主要晚期≥2级毒性为吞咽困难和牙关紧闭。
要点
- 根治性再程放疗后2年局部区域无失败生存率为18.3%(95%CI:7.1%-47.1%),总生存率为42.5%(95%CI:26.2%-69.1%)。
- 18例局部区域复发中8例(44.4%)发生在既往再程放疗野内,质子治疗组无病生存期显著更长(p=0.031)。
- 主要晚期≥2级毒性为吞咽困难和牙关紧闭,作者认为根治性再程放疗对部分筛选病例可行但局部复发率和毒性风险仍高。
核心结论
- 作者认为根治性再程放疗对部分筛选的复发头颈鳞状细胞癌病例可行,但照射野内局部区域复发率和≥2级毒性风险仍高。
研究设计与样本
- 2012年8月30日至2019年4月8日期间55例接受再程放疗的头颈癌患者中,23例为头颈鳞状细胞癌,接受IMRT(52.2%)或质子治疗(47.8%),CTV中位最大剂量66 Gy。
主要发现
- 中位随访41.3个月后,18例发生局部区域复发,其中8例(44.4%)位于既往再程放疗野内。
- 2年局部区域无失败生存率为18.3%(95%CI:7.1%-47.1%),2年总生存率为42.5%(95%CI:26.2%-69.1%)。
- 质子治疗组无病生存期较IMRT组显著更长(p=0.031)。
- 主要晚期≥2级毒性为吞咽困难和牙关紧闭。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze outcomes of patients treated with curative reirradiation (reRT), with intensity-modulated radiation therapy (IMRT) or proton therapy (PT) for recurrent head and neck squamous cell carcinoma (HNSCC). MATERIALS: Among the 55 patients reirradiated for head and neck cancer from 30/08/2012 to 08/04/2019, 23 had HNSCC and received IMRT (52.2%) or PT (47.8%) at a median maximum dose to the CTV of 66 Gy. RESULTS: After a median follow-up of 41.3 months, 18 patients developed a locoregional recurrence (LR), of which eight (44.4%) occurred within the previously reirradiated volume. Two-year locoregional failure-free survival and overall survival were 18.3%[95%CI:7.1%-47.1%] and 42.5%[95%CI:26.2%-69.1%], respectively. Disease-free survival was significantly longer in the PT group (p = 0.031). Main late grade ≥2 toxicities were dysphagia and trismus. CONCLUSION: Curative reRT in HNSCC is possible for selected cases, but the LR rate in the irradiated field and the risk of toxicity grade ≥2 remain high.
引用
- Beddok A, Saint-Martin C, Krhili S, et al. Curative high-dose reirradiation for patients with recurrent head and neck squamous cell carcinoma using IMRT or proton therapy: Outcomes and analysis of patterns of failure. Head Neck. 2022. PMID: 35875934. doi:10.1002/hed.27153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。